Ultra-Strong Machine Learning: comprehensibility of programs learned with ILP

During the 1980s Michie defined Machine Learning in terms of two orthogonal axes of performance: predictive accuracy and comprehensibility of generated hypotheses. Since predictive accuracy was readily measurable and comprehensibility not so, later definitions in the 1990s, such as Mitchell’s, tended to use a one-dimensional approach to Machine Learning based solely on predictive accuracy, ultimately favouring statistical over symbolic Machine Learning approaches. In this paper we provide a definition of comprehensibility of hypotheses which can be estimated using human participant trials. We present two sets of experiments testing human comprehensibility of logic programs. In the first experiment we test human comprehensibility with and without predicate invention. Results indicate comprehensibility is affected not only by the complexity of the presented program but also by the existence of anonymous predicate symbols. In the second experiment we directly test whether any state-of-the-art ILP systems are ultra-strong learners in Michie’s sense, and select the Metagol system for use in humans trials. Results show participants were not able to learn the relational concept on their own from a set of examples but they were able to apply the relational definition provided by the ILP system correctly. This implies the existence of a class of relational concepts which are hard to acquire for humans, though easy to understand given an abstract explanation. We believe improved understanding of this class could have potential relevance to contexts involving human learning, teaching and verbal interaction

Over-expression of a zeatin O-glucosylation gene in maize leads to growth retardation and tasselseed formation

To study the effects of cytokinin O-glucosylation in monocots, maize (Zea mays L.) transformants harbouring the ZOG1 gene (encoding a zeatin O-glucosyltransferase from Phaseolus lunatus L.) under the control of the constitutive ubiquitin (Ubi) promoter were generated. The roots and leaves of the transformants had greatly increased levels of zeatin-O-glucoside. The vegetative characteristics of hemizygous and homozygous Ubi:ZOG1 plants resembled those of cytokinin-deficient plants, including shorter stature, thinner stems, narrower leaves, smaller meristems, and increased root mass and branching. Transformant leaves had a higher chlorophyll content and increased levels of active cytokinins compared with those of non-transformed sibs. The Ubi:ZOG1 plants exhibited delayed senescence when grown in the spring/summer. While hemizygous transformants had reduced tassels with fewer spikelets and normal viable pollen, homozygotes had very small tassels and feminized tassel florets, resembling tasselseed phenotypes. Such modifications of the reproductive phase were unexpected and demonstrate a link between cytokinins and sex-specific floral development in monocots

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial

Abstract: Background: Parkinson’s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals’ needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The evidence-base for their effectiveness is inconclusive. Methods/design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation. Primary outcome: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales, Parkinson’s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12 months after randomisation. The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42 sites around the UK. Discussion: The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-effectiveness of both interventions. Trial registration: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382. Registered on 18 April 2016

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial

Abstract: Background: Parkinson’s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals’ needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The evidence-base for their effectiveness is inconclusive. Methods/design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation. Primary outcome: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales, Parkinson’s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12 months after randomisation. The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42 sites around the UK. Discussion: The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-effectiveness of both interventions. Trial registration: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382. Registered on 18 April 2016

Inhibition of carnation petal inrolling by growth retardants and cytokinins

Excised carnation petals induced to senescence by ethrel (an ethylene-releasing compound) exhibited morphological changes that closely resembled those of senescing petals in situ in cut flowers. The sensitivity of the excised petals to ethylene was reduced by exogenous cytokinin and this type of hormonal interaction in the control of plant development is discussed. Using the excised petals, a number of known and potential growth inhibitors were compared for ability to prevent petal inrolling induced by ethrel. Cycloheximide and 6-methylpurine were the most effective and inhibited inrolling almost completely, but purine, purine riboside, lauric acid, L-azetidine-2-carboxylic acid and n-decyl alcohol were also very effective. All these compounds were considerably more effective than any cytokinin tested. When supplied through the transpiration stream to short-stemmed carnations, cycloheximide, 6-methylpurine and purine inhibited inrolling nearly completely and the flowers finally senesced by water loss. 6-Methylpurine inhibited ethylene production in cut flowers and RNA synthesis in excised petals very markedly. Degradation of exogenous zeatin riboside by cytokinin oxidase, and the level of activity of the enzyme in petals, were reduced by 6-methylpurine. These biochemical changes probably account for the strong inhibition of inrolling induced by this compound

Risk and resilience factors reported by a New Zealand tertiary student population after the 4th September 2010 Darfield Earthquake

An online survey of 3,571 University of Canterbury tertiary students was undertaken four to six weeks after the Mw 7.1 Darfield (Canterbury) earthquake impacted Christchurch, New Zealand. The aim was to identify factors indicating increased psychological risk after the event, and so gauge the well-being of the student population, while gathering feedback on the University’s post-earthquake communication strategy. The majority of students reported diminished stress during aftershocks since the event, and 93% reported ‘feeling OK again’ at the time of survey completion. More than 95% reported being satisfied or very satisfied with the University’s communication strategy, and would recommend the University to other students. Students also reported concern about the potential impact of the earthquake on their academic performance. Heightened risk was associated largely with aspects of impact exposure. Established risk factors, such as damage to residences, were confirmed in these findings. Short absences from the city after the event were also associated with increased risk. Identifying significant risk factors, and indicating the importance of rapid and regular post-disaster communication, these findings are particularly relevant for those involved in tertiary institutional planning for future disaster events